AchieveRx reports $201.5m cash as smoking-cessation drug nears planned FDA refiling

AchieveRx, the company formerly known as Achieve Life Sciences, ended the third quarter of 2026 with $201.5m in cash. It gave the figure on 10 November alongside an update that keeps its only disclosed lead programme, the smoking-cessation drug cytisinicline, on course for a new US filing before the year ends.

The company said it has finished three stability batches of the drug made at commercial scale by its US manufacturer, Adare. Such batches typically feed the chemistry, manufacturing and controls section of a marketing application, so the milestone bears on the filing it intends to make in the fourth quarter. AchieveRx still expects the FDA could approve the product by the end of the second quarter of 2027.

It also presented 52-week data from the ORCA-OL study, with a quit rate of 31.2% and no new safety signals. The release does not say how the study population or the quit-rate measure were defined, so the figure cannot be compared directly with results for other cessation products.

Several points remain undisclosed in the material available: what the resubmission will contain, what FDA feedback shaped it, and how the stability data will be used in the file. The company also gave no revenue, launch-pricing or commercial-partnership information. The approval timeline is therefore a company expectation, not a regulatory commitment.